Search for drugs:
Typing the drug name to query
BEMPEDOIC ACID
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dose of 240 mg (1.3 times the approved recommended dose), bempedoic acid does not prolong the QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- C10AX15 - bempedoic acid
- C10AX - Other lipid modifying agents
- C10A - "LIPID MODIFYING AGENTS, PLAIN"
- C10 - LIPID MODIFYING AGENTS
- C - CARDIOVASCULAR SYSTEM
- C10BA10 - bempedoic acid
- C10BA - HMG CoA reductase inhibitors in combination with other lipid modifying agents
- C10B - "LIPID MODIFYING AGENTS, COMBINATIONS"
- C10 - LIPID MODIFYING AGENTS
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:Bempedoic Acid
Active Ingredient UNII:1EJ6Z6Q368
Drugbank ID:DB11936
PubChem Compound:10472693
CTD ID:C581236
CAS Number:738606-46-7
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.